GSK343 decreased tumor stemness. by Laura V. Bownes (10276762)

“…<p>(A) COA3 and (B) COA6 PDX cells were plated as single cell suspension in serum-free, conditioned media onto 96-well low attachment plates using serial dilutions with 5000, 1000, 100, 50, 20, 10, and 1 cell per well. …”

A decrease in CD44+ cells in response to hypoxia. by Daniel V. Brown (3797809)

Loss of Prox1a decreases PR production at 120 hours post-ablation. by Kellie Veen (17343374)

<i>Kdm6a</i> conditional KO mice have decreased repopulating potential in serial competitive transplantation assays. by Ling Tian (107492)

“…(C) Quantification of donor cell chimerism in hematopoietic stem cells (HSCs) in BM by flow cytometry 36 weeks after transplantation. …”

Rapamycin decreases Schwann cell markers, whereas statin induces Schwann cell markers. by Andrea Preitschopf (629851)

STAT3 inhibition in human neural stem cells leads to a decrease in neurosphere formation and proliferation, and an upregulation of Jmjd3 expression. by Maureen M. Sherry-Lynes (3911521)

Regional Volume Decreases in the Brain of <i>Pax6</i> Heterozygous Mutant Rats: MRI Deformation-Based Morphometry - Fig 5 by Kotaro Hiraoka (812730)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

H-MSCs^WT decrease myofibroblasts in peri-infarction region. by Panpan Chen (307628)

Subjects:

Imatinib decreases <i>in vivo</i> proliferation of T-cells. by Ludovic Belle (293091)

Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

“…Activity rates decreased during repeated stress compared to baseline (2-way ANOVA, condition F = 185.6, <i>p</i> = 4.8 × 10⁻⁴², condition: intensity interaction F = 10.37, <i>p</i> = 9.3 × 10⁻²¹, nested ANOVA (mouse nested within session), condition F = 174, <i>p</i> = 1.5 × 10⁻³⁹, condition: intensity interaction F = 12.7, <i>p</i> = 2 × 10⁻²⁶, post hoc for each level baseline versus repetitive stress <i>p</i> < 0.01 for all levels above 50 dB, all Bonferroni corrected). …”

Decreased ISCs and increased goblet cells after intestinal specific loss of MLL1. by Neha Goveas (11790822)

“…<p><b>(A)</b> Kaplan-Meier survival curve. Tamoxifen was given by gavage for 6 days to mice with the genotype <i>Mll1</i>^{<i>FC/+; Vil-Cre-ERT2/+</i>} (n = 12) and <i>Mll1</i>^{<i>FC/FC; RC/+</i>} (n = 18). …”

Naloxone reverses morphine increased-caspase-3 activity, neuronal differentiation and decreased NPC expression. by Dafna Willner (605895)

“…Morphine 13 =  Morphine 13 µM; Naloxone 50 =  Naloxone 50 µM (<b>6A, 6B</b>).</p>…”

Correlation between decreased ferroportin (Fpn) protein level and increased hepcidin (Hepc) mRNA expression in the liver of <i>ms/−</i> males. by Małgorzata Lenartowicz (150659)

Prolonged treatment with oxytocin does not decrease the neural stem cell pool. by Arvind Palanisamy (3159156)

The decrease in blood flow disrupts CV pruning. by Lin Wen (557398)

MBCD decreased stemness in MDA-MB-231. by Ankit Sharma (578833)

“…(<b>E</b>) RT-PCR analysis was performed using total RNA and gene specific primers. Decreased levels of stemness markers CD44 and BMI1 were found in MBCD treated cells. …”

Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration-6 by Sergio Liarte (75701)

“…<p><b>Copyright information:</b></p><p>Taken from "Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration"</p><p>http://www.rbej.com/content/5/1/20</p><p>Reproductive Biology and Endocrinology 2007;5():20-20.…”

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”